| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
EPSTEIN BARR (EBV) DNA, QUANTITATIVE PCR, PLASMA
MessageA prospective and diagnostic marker for the development of posttransplant lymphoproliferative disorders (PTLD), especially in
Epstein-Barr virus (EBV)-seronegative organ transplant recipients who receive anti-lymphocyte globulin for induction immunosuppression and
OKT-3 treatment for early rejection.
Epstein-Barr virus (EBV)-seronegative organ transplant recipients who receive anti-lymphocyte globulin for induction immunosuppression and
OKT-3 treatment for early rejection.
Test Code
LAB304550
CPT Codes
87799
Preferred Specimen
One 3 mL EDTA Lavender Top Tube
Minimum Volume
2.0 mL EDTA Whole Blood
Instructions
EDTA plasma must be separated from cells within 24 hours and plasma frozen (-20°C). A minimum 0.6 mL of plasma aliquot is
required.
required.
Transport Temperature
Frozen
Specimen Stability
Refrigerated: Plamsa 6 days
Frozen: Plasma 6 months (preferred)
Plasma must be separated from whole blood within 24 hours of collection.
Frozen: 5 days (EDTA plasma separated from redblood cells)
Frozen: Plasma 6 months (preferred)
Plasma must be separated from whole blood within 24 hours of collection.
Frozen: 5 days (EDTA plasma separated from redblood cells)
Methodology
Polymerase Chain Reaction (PCR)
Setup Schedule
Monday-Wednesday-Friday
Reference Range
"Target Not Detected"
Positive results are quantitated in IU/mL
Positive results are quantitated in IU/mL
Clinical Significance
This test is used to detect EBV DNA in blood specimens. A positive result supports the clinical diagnosis of EBV disease. However, a negative (target not detected) result does not eliminate the possibility of EBV. This assay may detect viremia or viral shedding in
asymptomatic individuals. However, this assay is only to be used for patients with a clinical history and symptoms consistent with EBV
infection, and must be interpreted in the context of the clinical picture. This test should not be used to screen asymptomatic patients.
Increasing copy levels of Epstein-Barr virus (EBV) DNA in serial specimens may indicate possible posttransplant lymphoproliferative
disorders (PTLD).
Epstein-Barr virus (EBV) is the causative agent of infectious mononucleosis, Burkitt lymphoma, and in southern China,
nasopharyngeal carcinoma. EBV-associated central nervous system (CNS) disease is most commonly associated with primary CNS
lymphoma in patients with AIDS. In addition, CNS infection associated with the detection of EBV DNA can be detected in immunocompetent
patients.
asymptomatic individuals. However, this assay is only to be used for patients with a clinical history and symptoms consistent with EBV
infection, and must be interpreted in the context of the clinical picture. This test should not be used to screen asymptomatic patients.
Increasing copy levels of Epstein-Barr virus (EBV) DNA in serial specimens may indicate possible posttransplant lymphoproliferative
disorders (PTLD).
Epstein-Barr virus (EBV) is the causative agent of infectious mononucleosis, Burkitt lymphoma, and in southern China,
nasopharyngeal carcinoma. EBV-associated central nervous system (CNS) disease is most commonly associated with primary CNS
lymphoma in patients with AIDS. In addition, CNS infection associated with the detection of EBV DNA can be detected in immunocompetent
patients.
Performing Laboratory
West Virginia University Hospital, Inc.
Additional Information
EBV Test Change Notification
